ALK5 Inhibitor II (hydrochloride) Catalog No.:M23387-C 5-difluoropyridin-2-yl)-4-(methanesulfonylmethyl)-15-methyl-14-oxo-8

5-difluoropyridin-2-yl)-4-(methanesulfonylmethyl)-15-methyl-14-oxo-8

InChi: InChI=1S/C35H38N6O6/c1-4-41-32(37-38-39-41)28-15-10-9-14-27(28)25-20-18-24(19-21-25)22-40-31-29(16-11-17-30(31)36-34(40)44-5-2)33(42)45-23(3)46-35(43)47-26-12-7-6-8-13-26/h9-11

Lucidin primeveroside (0

Smiles: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C2O[C@@H](CC(=O)C2=C(O)C=C1O)C1C=CC(O)=CC=1

Treatment of MEFs with WM-1119 results in cell cycle arrest in G1 and a senescence phenotype similar to that seen upon treatment with WM-8014

ALK5 Inhibitor II (hydrochloride) Catalog No.:M23387-C 5-difluoropyridin-2-yl)-4-(methanesulfonylmethyl)-15-methyl-14-oxo-8IC50: 4, 18, and 23 nM for ALK5 autophosphorylation, TGF cellular assay, and ALK5 binding in HepG2 cells, respectively ALK5 Inhibitor II is an ALK5 inhibitor. The TGF beta family of cytokines signal via serine threonine kinase transmembrane type I and type II receptors. Binding TGF beta1 to the receptor complex triggers activation of activin receptor like kinase (ALK), initiating downstream signaling involving Smad transcription factors, mitogen